The development of new medicines for the successful treatment of cervical and liver malignancies is critical in order to address the disadvantages of current chemotherapeutics, such as increased resistance. Metal ion-based chemical complexes have recently emerged as a prominent method for cancer therapy. As a result, the study aims to create novel anticancer medicines based on leads acquired through combinatorial chemistry of metal complexes. Cobalt (III) Schiff base trans- [Co(salen)(DA)2](ClO4) (complex 1) and trans-[Co (salophen)(DA)2](ClO4) (complex 2)] where, the salen and salopen were N, N′-bis(salicylidene) ethylenediamine, and N, N′-bis(salicylidene)-1,2- phenylenediamine, DA: dodecylamine) were synthesized as an alternative to the existing drugs, and their cytotoxic effect were evaluated against human cervical (HeLa) and liver cancer cell lines (HepG2) using MTT viability assay, and apoptotic morphological staining which including Acridine Orange/Ethidium Bromide (AO/EB), Hoechst 33528, Annexin V-Cy3 assay, JC-1 staining Comet assay, and reactive oxygen species (ROS) assay. Further the apoptosis was confirmed with immunocytochemistry and real-time reverse transcription-polymerase chain reaction (RT-PCR). The results indicated that cobalt (III) complexes reduced the viability of the HeLa and HepG2 cell lines at their half minimum lethal doses, with cell death induced mainly via apoptotic pathway. Hence, the cobalt complexes 1 and 2 could be act as an effective drug for cervical and liver cancers.